Bone Biologics raises $3 million in private placement
BBLG•Use of proceeds and runway
Net proceeds are earmarked for clinical trials, patent portfolio work, working capital and general corporate purposes.
The company expects the financing to extend its operating runway through Q2 2027.
Private placement completed with healthcare-focused investor
Bone Biologics completed a July 2026 private placement with a single healthcare-focused institutional investor, raising about $3 million in gross proceeds.
The deal was priced at-the-market under Nasdaq rules.
The financing included Series F warrants and Series G warrants; full cash exercise could add up to about $6 million in gross proceeds.
